Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC

Abstract Background Hepatocellular carcinoma (HCC) ranks sixth amongst all cancers and is the 2nd top cause of mortality attributable to cancer. Aim of the work This study aimed to ascertain the sustained virological response (SVR) to interferon-free regimens in chronic people with HCV after the suc...

Full description

Saved in:
Bibliographic Details
Main Authors: Amr Maged Mahmoud Rasheed, Maissa E. L. Raziky, Mohammad El Sayed, Mai Mehrez, Gamal Esmat
Format: Article
Language:English
Published: SpringerOpen 2025-02-01
Series:Egyptian Liver Journal
Subjects:
Online Access:https://doi.org/10.1186/s43066-025-00406-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832572036122148864
author Amr Maged Mahmoud Rasheed
Maissa E. L. Raziky
Mohammad El Sayed
Mai Mehrez
Gamal Esmat
author_facet Amr Maged Mahmoud Rasheed
Maissa E. L. Raziky
Mohammad El Sayed
Mai Mehrez
Gamal Esmat
author_sort Amr Maged Mahmoud Rasheed
collection DOAJ
description Abstract Background Hepatocellular carcinoma (HCC) ranks sixth amongst all cancers and is the 2nd top cause of mortality attributable to cancer. Aim of the work This study aimed to ascertain the sustained virological response (SVR) to interferon-free regimens in chronic people with HCV after the successful treatment of hepatocellular carcinoma, as well as the percentage of persons who would demonstrate any radiological or laboratory alterations indicating a local or de novo recurrence of HCC. Patients and methods This trial was carried out on 90 Egyptian persons with chronic HCV infection who were eligible for treatment with oral antiviral agents (DAAs) with hepatic focal lesion(s). Patients were referred to from both the outpatient clinic and hepatocellular carcinoma clinic at the National Hepatology and Tropical Medicine Research Institute (NHTMRI), and the trial was conducted in the period between October 2017 and May 2021. Results Four patients with distant metastasis, three dying from liver-related incidents, received surgical resection, TACE, and RFA treatment, while one patient survived with compensated chronic liver disease. By multivariate logistic regression, we found that AFP is an independent predictor of HCC recurrence, while baseline urea level and FIB4 before antiviral therapy protect against recurrence. PLT was the best predictor, with AFP having a sensitivity of 52% and specificity of 93.8% at a cutoff value of 135 and PCR having a sensitivity of 72%. Conclusion The HCC recurrence rate was 27.8%, slightly higher than the estimated annual HCC recurrence rate following curative procedures (20%).
format Article
id doaj-art-e04434767c48418f8c5cd0ce2a2ce5c7
institution Kabale University
issn 2090-6226
language English
publishDate 2025-02-01
publisher SpringerOpen
record_format Article
series Egyptian Liver Journal
spelling doaj-art-e04434767c48418f8c5cd0ce2a2ce5c72025-02-02T12:09:23ZengSpringerOpenEgyptian Liver Journal2090-62262025-02-011511810.1186/s43066-025-00406-2Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCCAmr Maged Mahmoud Rasheed0Maissa E. L. Raziky1Mohammad El Sayed2Mai Mehrez3Gamal Esmat4Hepatology and Gastroenterology Department, National Hepatology and Tropical Medicine Research Institute (NHTMRI)Endemic Medicine Department, Faculty of Medicine, Cairo UniversityEndemic Medicine Department, Faculty of Medicine, Cairo UniversityHepatology and Gastroenterology Department, National Hepatology and Tropical Medicine Research Institute (NHTMRI)Endemic Medicine Department, Faculty of Medicine, Cairo UniversityAbstract Background Hepatocellular carcinoma (HCC) ranks sixth amongst all cancers and is the 2nd top cause of mortality attributable to cancer. Aim of the work This study aimed to ascertain the sustained virological response (SVR) to interferon-free regimens in chronic people with HCV after the successful treatment of hepatocellular carcinoma, as well as the percentage of persons who would demonstrate any radiological or laboratory alterations indicating a local or de novo recurrence of HCC. Patients and methods This trial was carried out on 90 Egyptian persons with chronic HCV infection who were eligible for treatment with oral antiviral agents (DAAs) with hepatic focal lesion(s). Patients were referred to from both the outpatient clinic and hepatocellular carcinoma clinic at the National Hepatology and Tropical Medicine Research Institute (NHTMRI), and the trial was conducted in the period between October 2017 and May 2021. Results Four patients with distant metastasis, three dying from liver-related incidents, received surgical resection, TACE, and RFA treatment, while one patient survived with compensated chronic liver disease. By multivariate logistic regression, we found that AFP is an independent predictor of HCC recurrence, while baseline urea level and FIB4 before antiviral therapy protect against recurrence. PLT was the best predictor, with AFP having a sensitivity of 52% and specificity of 93.8% at a cutoff value of 135 and PCR having a sensitivity of 72%. Conclusion The HCC recurrence rate was 27.8%, slightly higher than the estimated annual HCC recurrence rate following curative procedures (20%).https://doi.org/10.1186/s43066-025-00406-2HCVHCCCirrhosisDAAsSVRRFA
spellingShingle Amr Maged Mahmoud Rasheed
Maissa E. L. Raziky
Mohammad El Sayed
Mai Mehrez
Gamal Esmat
Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
Egyptian Liver Journal
HCV
HCC
Cirrhosis
DAAs
SVR
RFA
title Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
title_full Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
title_fullStr Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
title_full_unstemmed Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
title_short Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
title_sort impact of interferon free regimens in patients with chronic hcv and successfully ablated hcc
topic HCV
HCC
Cirrhosis
DAAs
SVR
RFA
url https://doi.org/10.1186/s43066-025-00406-2
work_keys_str_mv AT amrmagedmahmoudrasheed impactofinterferonfreeregimensinpatientswithchronichcvandsuccessfullyablatedhcc
AT maissaelraziky impactofinterferonfreeregimensinpatientswithchronichcvandsuccessfullyablatedhcc
AT mohammadelsayed impactofinterferonfreeregimensinpatientswithchronichcvandsuccessfullyablatedhcc
AT maimehrez impactofinterferonfreeregimensinpatientswithchronichcvandsuccessfullyablatedhcc
AT gamalesmat impactofinterferonfreeregimensinpatientswithchronichcvandsuccessfullyablatedhcc